Clinical Trials
116 trialsPRO-NEM1
Centre Hospitalier Universitaire Dijon
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
iCaRe2
University of Nebraska
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
PRRT
Methodist Health System
Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data
Huazhong University of Science and Technology
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
University of California, Davis
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
CardioNETPOL
National Institute of Cardiology, Warsaw, Poland
LINEAR
European Institute of Oncology
TNE-bien-DIF
Assistance Publique - Hôpitaux de Paris
FARINET
IRCCS San Raffaele
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
First Affiliated Hospital of Zhejiang University
DENUTNE
University Hospital, Strasbourg, France
NET-PRO
University of Iowa
ETP-NET
Hospices Civils de Lyon
NIP IT!
University Health Network, Toronto
GAPET-NET
University Hospital, Brest
AURA-RIV-TNE
Hospices Civils de Lyon
GEP-NENs
Tongji Hospital
TAILOR-EUS
IRCCS San Raffaele
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Nanjing First Hospital, Nanjing Medical University
REBORN
University of Roma La Sapienza
NUTRIGETNE
Grupo Espanol de Tumores Neuroendocrinos
ANZ UGI
Western Sydney Local Health District
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
First Affiliated Hospital, Sun Yat-Sen University
JPET2Clinic
Jagiellonian University
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
Latin American Cooperative Oncology Group
TEGRELE
Central Hospital, Nancy, France
NETAT
University of Pennsylvania
NEMESIs
University Hospital, Basel, Switzerland
AIM-NETs
Asan Medical Center
EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms
European Institute of Oncology
ECHO-NET
Istituto Clinico Humanitas
SurvivApp
Insel Gruppe AG, University Hospital Bern
PitNET2024
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
Fujian Maternity and Child Health Hospital
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
ETNA-FPG
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
BANN
University Medical Center Groningen
VIDEO-NET
University Medical Center Groningen
5-HIAA
University Medical Center Groningen
HET-NET
University Medical Center Groningen
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
University Medical Center Groningen
TAPIOCA
European Institute of Oncology
SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
Peking Union Medical College Hospital
YOUNGSTER
European Institute of Oncology
FiReNEN
IRCCS San Raffaele
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Qilu Hospital of Shandong University
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.
IRCCS San Raffaele